MOUNTAIN VIEW, Calif. & GOTHENBURG, Sweden--(BUSINESS WIRE)--Glooko, the leader in diabetes data management, today announced participation in the 78th Annual American Diabetes Association (ADA) meeting taking place this weekend in Orlando, Fla. At the event, Glooko will demonstrate the new version 5.0 of its diabetes management mobile application and will share results from a recent human factors study on its Mobile Insulin Dosing System (MIDS) for long-acting insulin (LAI) titration, which was FDA cleared earlier this year.
With over 95% of glucose, insulin pump and exercise devices supported, the new Glooko Mobile App focuses on features that add context to glucose and insulin data. Version 5.0 makes tracking personal lifestyle events like exercise, food and medication easier and faster. The new release includes:
- Capture of daily steps from Apple devices including the iPhone and Apple Watch through Apple Health
- Visual food logging in a new “shopping cart” layout that allows for quick identification of foods using real-world pictures and the tracking of multiple foods at once
- Personalized and streamlined event logging (food, medications, insulins, exercise, notes) that remembers recent entries and allows for quick re-entry
“Glooko’s universal platform for diabetes data management not only seamlessly captures data from most diabetes devices in the market, but now makes lifestyle tracking easier than ever before,” said Dave Conn, Chief Commercial Officer at Glooko. He continued, “Adding further insights like food, medication, insulin, exercise and notes about mood, feelings and behaviors provides relevant context to an individual’s glucose readings and helps people with diabetes and clinicians better augment self-care and the overall clinical care plan.”
In addition to demonstrating the new Glooko Mobile App and the recently released version of the Glooko Web App, Glooko will also be presenting a poster at the ADA conference on Saturday, June 23, from 11:30-12:30 pm. The poster covers the results from a recent human factors study on the MIDS application – proving that MIDS is simple, effective, and easy-to-use for people with type 2 diabetes of varying ages, LAI experience, and smartphone use without training or reading a user manual. Participants reported overwhelmingly positive feedback and no participant expressed frustration when completing tasks despite any lack of training or prior experience with digital diabetes tools.
To learn more visit us in booth #1137 on the exhibition floor or come see our poster in the General Poster Session, Category 12-C Clinical Therapeutics/New Technology- Insulins #1055-P.
Glooko provides insights that improve outcomes for people with diabetes (PWDs) and their care teams. Glooko syncs data from the world’s most popular diabetes devices and major fitness and activity trackers and supplies personalized, timely insights based on blood glucose, food, insulin, blood pressure, diet and weight data. Trusted by the world’s leaders in diabetes care, Glooko is used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com
©2018 Glooko, Inc. Glooko and Diasend are trademarks of Glooko, Inc. All rights reserved. PRM 0504 Rev A